Search

Displaying results 2111 - 2120 of 7538 in total
  1. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. … [L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant.

  2. Drug

    Abatacept

    go.drugbank.com/drugs/DB01281
    ApprovedInvestigational

    The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. … Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human

  3. Drug

    Ceftaroline fosamil

    go.drugbank.com/drugs/DB06590
    ApprovedInvestigational

    Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections

  4. Drug

    Tetrachlorodecaoxide

    go.drugbank.com/drugs/DB05389
    Approved

    The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the … WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers.

  5. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway. … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.

  6. Drug

    Sodium tartrate

    go.drugbank.com/drugs/DB13707
    ApprovedWithdrawn

    This compound is commonly used as an emulsifier in cheese/cheese spread products and is not to exceed 4% concentration, according to Health Canada regulations [L2594]. … Sodium tartrate is a disodium salt of l-( + )-tartaric acid that is identified by transparent, colorless, and odorless crystals. It is obtained as a byproduct of wine manufacturing.

  7. Drug

    Colistimethate

    go.drugbank.com/drugs/DB01111
    ApprovedInvestigationalVet approved

    Colistimethate is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa. … Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms.

  8. Drug

    Mefenamic acid

    go.drugbank.com/drugs/DB00784
    Approved

    A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticSynonyms: N-2,3-xylylanthranilic acid, N-(2,3-xylyl)-2-aminobenzoic acid
  9. Drug

    Romiplostim

    go.drugbank.com/drugs/DB05332
    ApprovedInvestigational

    Interestingly, romiplostim's amino acid sequence is not similar to that of endogenous thrombopoietin. Romiplostim is produced by recombinant DNA technology in Escherichia coli. … FDA approved on August 22, 2008.

  10. Drug

    Ximelagatran

    go.drugbank.com/drugs/DB04898
    ApprovedWithdrawn

    Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. … In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries

    Synonyms: ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetate